As a scientist and entrepreneur with a deep understanding of business fundamentals, I bring a wealth of experience in research and development to my role. My extensive scientific background has equipped me with critical thinking skills, allowing me to recognize new market opportunities with a sharp eye.
I am currently the Co-founder and CEO of EvoDenovo, a biotech company dedicated to developing innovative solutions for reducing substance use disorder dependence. Our team is focused on developing a game-changing drug that suppresses opioid withdrawal and tolerance while retaining strong analgesic abilities. This work builds on my past experiences as a co-founder of several other biotech companies, including Genma bio-Inc. and Artus Therapeutics Inc.
My past scientific work, conducted under the guidance of Dr. Javier Irazoqui and Dr. Fred Ausubel at Massachusetts General Hospital/Harvard Medical School, involved the identification of new players in pathogen detection by the nervous system. As an entrepreneur, I have a passion for driving progress in research and development, and I am committed to bringing my extensive experience in biotech operations, business development, and preclinical drug development to the forefront in support of new and innovative ideas.
I am always eager to connect with others in the biotech community, and I am excited to be part of an industry that has the potential to make a profound impact on human health and well-being.